Golidocitinib Plus Anthracycline-based Therapy for Untreated Nodal T-follicular Helper (TFH) Cell Lymphoma

Key inclusion Criteria:

• Histologically confirmed nodal T-follicular helper (TFH) cell lymphoma according to the 2022 WHO classification.
• Previously untreated with systemic anti-lymphoma therapy.
• Age ≥18 and <75 years.
• At least one measurable or evaluable lesion according to the Lugano 2014 criteria.
• An expected survival time of more than 12 weeks.
• An ECOG performance status score of 0-1.
• Adequate organ and bone marrow function.
• Provision of written informed consent and willingness to comply with all study procedures.

Key exclusion Criteria:

• Hemophagocytic syndrome.
• Central nervous system or meningeal involvement by lymphoma.
• Patients with a history of other malignancies within the past 5 years or concurrent malignancies, except for basal cell carcinoma of the skin.
• Patients receiving potent CYP3A inducers or inhibitors, vitamin K antagonists, antiplatelet agents, or anticoagulants.
• Patients with active infections, including tuberculosis, HIV infection, active hepatitis B, or active hepatitis C.
• Patients with severe or uncontrolled cardiovascular disease.
• Patients with a history of interstitial lung disease, except for asymptomatic radiation-induced interstitial lung disease.
• Patients with gastrointestinal conditions that may interfere with oral administration or drug absorption.
• Patients with known hypersensitivity to golidocitinib or its excipients.
• Pregnant or breastfeeding women and participants of childbearing potential unwilling to use effective contraception.
• Patients who have received systemic corticosteroids or other immunosuppressive therapy within 14 days before the start of study treatment.
• Patients considered unsuitable for participation by the investigator.